74 results
8-K
EX-99.1
TSHA
Taysha Gene Therapies Inc
10 Jan 24
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
12:00am
expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential benefits and clinical
8-K
EX-10.1
TSHA
Taysha Gene Therapies Inc
20 Dec 23
Departure of Directors or Certain Officers
4:21pm
calculating any Participant’s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly
S-8
EX-99.1
lpcwgjk8xjk4j85h3
20 Dec 23
Registration of securities for employees
4:20pm
8-K
EX-99.1
wneprxr51rp
26 Sep 23
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
8:08am
8-K
EX-99.1
nog7mofp 5lk3pzn
19 Sep 23
Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development
4:09pm
8-K
EX-99.1
dmcrm2u4
24 Aug 23
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
8:09am
8-K
EX-10.1
d0y33xnaxhnzpiypumhj
14 Aug 23
Entry into a Material Definitive Agreement
7:29am
8-K
EX-99.1
13t8k94d
19 May 23
Other Events
8:28am
PRE 14A
jomc0zxs
27 Apr 23
Preliminary proxy
4:03pm
8-K
EX-1.1
dln6lf
27 Oct 22
Taysha Announces Pricing of Public Offering of Common Stock
5:18pm